EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age

Agnaldo Lopes da Silva-Filho iD, Suvarna Khadilkar, Hema Divakar, Chiara Benedetto, Andrea R Genazzani, Diana Ramos, Elizabete Argale, Enrique Herrera, Martha Hickey

International Journal of Gynecology & Obstetrics · 2026-09 · 174 (3) · 1151-1171

DOI: 10.1002/ijgo.71188 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 22.07.2026. Verfasst von Agnaldo Lopes da Silva-Filho und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, Cancer Survivors, Menopause, Postmenopause. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advances in cancer screening, diagnosis, and treatment have greatly improved survival rates among women with gynecologic cancers. More survivors now live long enough to experience treatment‐related menopause. Vasomotor symptoms, genitourinary syndrome of menopause, sexual dysfunction, sleep issues, and long‐term risks from estrogen deficiency can seriously impact quality of life. Despite increased survival, managing menopausal symptoms remains difficult, as concerns about cancer recurrence and hormone therapy safety often result in inconsistent or insufficient treatment. This article explores clinical considerations for menopausal hormone therapy (MHT) in women with a history of gynecologic cancer. It reviews evidence on the safety of MHT after vulvar, vaginal, cervical, uterine, and ovarian cancers, providing an overview of tumor histology, stage, and hormonal sensitivity. It also synthesizes observational studies, systematic reviews, and international guidelines to help clinicians deliver menopausal care to cancer survivors. Current evidence suggests that systemic MHT may be suitable for carefully chosen survivors of non–hormone‐dependent gynecologic cancers, including most vulvar, vaginal, cervical, and epithelial ovarian cancers. Patients with hormonally sensitive tumors should generally avoid systemic MHT, while local vaginal hormonal administration and non‐hormonal options remain important in these cases. Given the disproportionate burden of gynecologic cancers in low‐ and middle‐income countries, where younger women face increased risks of treatment‐induced menopause and limited survivorship resources, this paper emphasizes context‐specific, resource‐aware strategies to promote equitable care. By enhancing personalized and evidence‐based decision‐making, we aim to improve quality of life for women during menopause after cancer treatment, while ensuring safe, fair, and widely applicable survivorship approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genital Neoplasms, FemaleCancer SurvivorsMenopausePostmenopauseEstrogen Replacement TherapyHormone Replacement TherapyHumansFemaleQuality of LifeMiddle Aged

Stichwörter der Autor:innen

cancer survivorsfemale genital neoplasmsgenitourinary syndrome of menopausehormone replacement therapyhot flashespremature menopausequality of lifetreatment‐induced menopause

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
  • FIGO Committee on Women at Menopausal Age, FIGO, London, UK.
  • Gynecology and Obstetrics Department, Bombay Hospital Institute of Medical Sciences, Mumbai, India.
  • Bombay Hospital Medical Research Center, Mumbai, India.
  • FIGO Division of Well Woman HealthCare, FIGO, London, UK.
  • Divakar Specialty Hospital, Bengaluru, Karnataka, India.

ORCID-Profile: Agnaldo Lopes da Silva-Filho

Zitieren

APA

da Silva-Filho, A. L., Khadilkar, S., Divakar, H., Benedetto, C., Genazzani, A. R., Ramos, D., Argale, E., Herrera, E., & Hickey, M. (2026). Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age. International Journal of Gynecology & Obstetrics, 174(3), 1151-1171. https://doi.org/10.1002/ijgo.71188

Vancouver

da Silva-Filho AL, Khadilkar S, Divakar H, Benedetto C, Genazzani AR, Ramos D, et al. Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age. International Journal of Gynecology & Obstetrics. 2026;174(3):1151-1171. doi:10.1002/ijgo.71188

BibTeX
@article{daSilvaFilho2026,
  author = {da Silva-Filho, Agnaldo Lopes and Khadilkar, Suvarna and Divakar, Hema and Benedetto, Chiara and Genazzani, Andrea R and Ramos, Diana and Argale, Elizabete and Herrera, Enrique and Hickey, Martha},
  title = {Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2026},
  volume = {174},
  number = {3},
  pages = {1151--1171},
  doi = {10.1002/ijgo.71188}
}
Kostenlos starten →